Listen to this post

As we close the book on 2025 and look ahead, we can’t help but feel a strong sense that we’ve been here before. 

On the one hand, with the federal government potentially eradicating consumable hemp in November and the president ordering urgent action on marijuana rescheduling in December, it may not be an exaggeration to say  the final 50 days of 2025 were among the most consequential of the past 50 years for the cannabis industry. 

On the other hand, rescheduling and the fate of hemp-derived consumables always seem to dominate discussions in our space.  Look no further than our 2025 predictions piece [https://www.buddingtrendsblog.com/2025/01/predictions-2025-to-be-a-very-big-year-in-cannabis/]. Even though the topics feel familiar, there is noticeably more urgency in the air this time around. Rescheduling is far from certain but seems more likely than ever. And the entire consumable hemp industry is on the brink of extinction if Congress does not change the law in the coming year.  

Our hit rate on predictions last year wasn’t where we wanted it to be, so we’re due. In that spirit, we once again share our premonitions about the year in cannabis: the 2026 edition.

2026 Will Be the Year for Real Movement in Rescheduling.  Right?

We and many others have written about President Trump’s much-touted Dec. 18 ceremony and executive order on rescheduling marijuana and increasing access to certain hemp products. We won’t again pontificate on what this could mean for the industry; if you’re curious, please read our earlier posts. Instead, we’ll explain why we believe the rescheduling process may truly be realized in the coming year. 

President Trump ordered Attorney General Pam Bondi to reschedule marijuana from Schedule I to Schedule III on an “expedited” basis. The expediency is possible this time, at least initially, because one important step has already occurred: The Department of Health and Human Services (HHS) recommended  rescheduling in 2023.

That means the DEA can move more quickly through its notice-and-comment rulemaking phase under  the Administrative Procedure Act. That process began in May 2024, when the DEA published a notice of proposed rulemaking in the Federal Register. 

Public comments followed, and in droves, totaling a record of 43,000 submissions. Now the DEA must resume (if it ever started) its review and consideration of those comments and respond as appropriate. The agency cannot ignore significant comments when issuing a final rule.

So while this administration has  a head start, important legal steps remain. After the comment evaluation and response period concludes, procedural challenges must be resolved, administrative hearings may be conducted, and a final rule issued. That rule will almost certainly be subject to judicial review, along with the process that produced it. Lawsuits are also expected, and some have already been filed.

It’s worth noting that Attorney General Bondi has not historically been an ally of the marijuana industry in her prior roles. We believe, however, that any reticence will be outweighed by her interest in keeping her current job. 

In sum, while President Trump’s executive order  does not itself reschedule marijuana, it clearly signal this administration’s desire to make rescheduling  a priority and to achieve it as expeditiously as possible. We expect substantive movement, if not a final rule, in 2026. The wild card, as always, is litigation and its ability to delay or disrupt the process. 

Consumable Hemp Takes a Step Back, but It’s Still Alive

An unexpected component of President Trump’s rescheduling executive order was the lifeline it threw to the hemp industry. The order instructs senior White House staff to work with Congress to redefine what constitutes legal hemp, just a month Congress, during a November 2025 government reopening, , effectively banned  consumable hemp products. 

We’ve already discussed what the order says. The question now is: What practically changes?

We predict the outright ban that has kept hemp operators up at night will not come to fruition. That said, we do not anticipate a return to the consumable hemp industry’s 2023-24 glory years. The most likely outcome is a hemp landscape dominated by CBD-forward and low-THC products, with higher-THC products relegated to state-legal marijuana programs.

State Programs Will Largely Remain Status Quo

The state-legal cannabis industry has, in most states, struggled to stay above water at best, and has experienced steady declines at worst. These trends have driven contraction, consolidation and downsizing. There are outliers, to be sure, but by and large the industry badly needs a shot in the arm.

Enter rescheduling. The tax relief alone, namely, removing marijuana from the reach of Section 280E, would open operators’ access to capital, potentially leading to growth, expansion and healthier economic activity.

Still, because we don’t expect the full effects of rescheduling to be  felt in 2026, we predict the year will largely serve as a planning period. Operators will begin preparing for a Schedule III world and evaluating how best to maximize the opportunities  rescheduled marijuana may offer.

Supreme Court Will Find Federal Gun Ban for Drug Users Unconstitutional

This one may seem like a bit of a flyer. What happens when a Supreme Court with an expansive view of the Second Amendment encounters a case involving marijuana, perhaps not the current majority’s product?  

We recently wrote about the court’s refusal to review the Sirois case, which likely would have required the justices to decide whether the Commerce Clause permits Congress to regulate purely intrastate marijuana markets. Our view is that while the court may be interested in clarifying Commerce Clause jurisprudence, it is far less eager to do so in a way that appears to liberalize marijuana policy. 

So how will the court resolve these competing interests? We believe it will lean into its recent Second Amendment rulings and conclude that marijuana users may not categorically prohibited from gun ownership. We’ll be watching closely to see whether any language in such an opinion encourages, or discourages, broader challenges to federal marijuana laws. 

Conclusion 

That’s it, folks. Predictions are hard, especially about the future. And free advice is worth exactly what you pay for it. Still, this is our best bet for the year ahead in cannabis.

One thing you can count on: Your friends at Budding Trends will be here to bring you the developments as they happen.   Thanks, as always, for stopping by and here’s to a big year ahead. Cheers.

Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of Whitt Steineker Whitt Steineker

As co-chair of Bradley’s Cannabis Industry team, Whitt represents clients in a wide range of cannabis issues. In addition to providing a full suite of legal services to cannabis companies, Whitt and the Cannabis Industry team advise non-cannabis clients – from banks to…

As co-chair of Bradley’s Cannabis Industry team, Whitt represents clients in a wide range of cannabis issues. In addition to providing a full suite of legal services to cannabis companies, Whitt and the Cannabis Industry team advise non-cannabis clients – from banks to commercial real estate companies to insurance companies and high net worth individuals – on best practices for interacting with cannabis companies.

Whitt is one of the leading voices in the cannabis bar – recognized as a “Go-To Thought Leader” by the National Law Review. He has presented on cannabis issues at conferences around the country.  His work has been featured in the National Law JournalLaw360, and the Westlaw Journal. And he has been quoted in an array of legal and mainstream publications from Law360 and Super Lawyers to the Atlanta Journal-Constitution and the Associated Press.

Photo of Slates C. Veazey Slates C. Veazey

Slates is a member of Bradley’s Cannabis Industry team, advising clients on a variety of cannabis issues and in a wide range of sectors. From individuals and entities interested in participating in the new Mississippi medical cannabis program to non-plant-touching companies impacted by…

Slates is a member of Bradley’s Cannabis Industry team, advising clients on a variety of cannabis issues and in a wide range of sectors. From individuals and entities interested in participating in the new Mississippi medical cannabis program to non-plant-touching companies impacted by that emerging market, Slates and his partners provide the full suite of services that Bradley offers to its many other clients — but with a specific understanding of the ever-changing cannabis industry. His work has been featured in The National Law Journal, JD Supra, and the Cannabis Business Executive. Slates also has been quoted by the Mississippi Business Journal and Mississippi Today regarding Mississippi’s medical cannabis program.